Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Fei Fei, MD, Yingzhe Yu, Anita Schmitt, MD, Jinfei Chen, PhD, MD, Baoan Chen, PhD, MD, Markus Rojewski, MD, Mark Ringhoffer, MD, Stefanie von Harsdorf, MD, Jochen Greiner, PhD, MD, Marlies Goetz, Philippe Guillaume, PhD, Hartmut Dohner, PhD, MD, Donald Bunjes, PhD, MD, Michael Schmitt, PhD, MD

Blood (2007) 110 (11): 2368.

https://doi.org/10.1182/blood.V110.11.2368.2368

Published: 2007

Journal Articles

Streptamer Technology for the Assessment of CMVpp65 Specific CD8+ T Cell Frequencies and for the Adoptive T Cell Transfer to Post-Transplant Patients.

Anita Schmitt, MD, Junxia Yao, MD, Hermann Einsele, PhD, MD, Ulrich Grigoleit, MD, Dirk Busch, PhD, MD, Manuel Odendahl, MD, Lothar Germeroth, PhD, Torsten Tonn, PhD, MD, Markus Wiesneth, MD, Markus Rojewski, MD, Clemens Bechter, Stefanie von Harsdorf, MD, Hartmut Dohner, PhD, MD, Donald Bunjes, PhD, MD, Michael Schmitt, PhD, MD

Blood (2007) 110 (11): 1964.

https://doi.org/10.1182/blood.V110.11.1964.1964

Published: 2007

Journal Articles

Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.

Jochen Greiner, MD, Jan Torzewski, MD, Peter Ponsaerts, PhD, Markus T. Rojewski, PhD, Desiree Kronawitter, PhD, Hubert Schrezenmeier, MD, Vinzenz Hombach, MD, Hartmut Dohner, MD, Michael Schmitt, PhD, Markus Wiesneth, MD, Oliver Zimmermann, MD, Juliane M. Wiehe, PhD

Blood (2006) 108 (11): 5471.

https://doi.org/10.1182/blood.V108.11.5471.5471

Published: 2006

Journal Articles

RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.

Michael Schmitt, PhD, Anita Schmitt, MD, Krzysztof Giannopoulos, MD, Li Li, PhD, Peter Liebisch, MD, Jinfei Chen, MD, Mark Ringhoffer, MD, Phillipe Guillaume, PhD, Gerd Ritter, PhD, Markus Rojewski, PhD, Sascha Gnjatic, PhD, Hartmut Dohner, MD, Jochen Jochen, MD

Blood (2006) 108 (11): 409.

https://doi.org/10.1182/blood.V108.11.409.409

Published: 2006

Journal Articles

Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.

Jochen Greiner, MD, Michael Schmitt, PhD, Li Li, PhD, Krzysztof Giannopoulos, MD, Katrin Bosch, Konstanze Dohner, MD, Anita Schmitt, MD, Richard F. Schlenk, MD, Jonathan R. Pollack, PhD, Hartmut Dohner, MD, Lars Bullinger, MD

Blood (2006) 108 (11): 414.

https://doi.org/10.1182/blood.V108.11.414.414

Published: 2006

Journal Articles

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Jinfei Chen, MD, Anita Schmitt, MD, Baoan Chen, MD, Markus Rojewski, MD, Jochen Greiner, MD, Philippe Guillaume, PhD, Hartmut Dohner, MD, Donald Bunjes, MD, Michael Schmitt, PhD

Blood (2006) 108 (11): 2201.

https://doi.org/10.1182/blood.V108.11.2201.2201

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Streptamer Technology for the Assessment of CMVpp65 Specific CD8+ T Cell Frequencies and for the Adoptive T Cell Transfer to Post-Transplant Patients.

Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.

RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.

Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Email alerts

ASH Publications

American Society of Hematology

Update search

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Streptamer Technology for the Assessment of CMVpp65 Specific CD8+ T Cell Frequencies and for the Adoptive T Cell Transfer to Post-Transplant Patients.

Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.

RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.

Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only